🚀 VC round data is live in beta, check it out!
BGM Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for BGM Group and similar public comparables like Türk İlaç, TScan Therapeutics, Oncocross, Annovis Bio and more.
BGM Group Overview
About BGM Group
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Founded
2019
HQ
Employees
323
Website
Sectors
Financials (FY)
EV
$54M
BGM Group Financials
BGM Group reported last fiscal year revenue of $25M and EBITDA of $880K.
In the same fiscal year, BGM Group generated $4M in gross profit, $880K in EBITDA, and had net loss of ($1M).
BGM Group P&L
In the most recent fiscal year, BGM Group reported revenue of $25M and EBITDA of $880K.
BGM Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $25M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 16% | XXX | XXX | XXX |
| EBITDA | — | XXX | $880K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 4% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (6%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BGM Group Stock Performance
BGM Group has current market cap of $66M, and enterprise value of $54M.
Market Cap Evolution
BGM Group's stock price is $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54M | $66M | 6.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBGM Group Valuation Multiples
BGM Group trades at 2.1x EV/Revenue multiple, and 60.9x EV/EBITDA.
BGM Group Financial Valuation Multiples
As of April 19, 2026, BGM Group has market cap of $66M and EV of $54M.
Equity research analysts estimate BGM Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BGM Group has a P/E ratio of (46.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $66M | XXX | $66M | XXX | XXX | XXX |
| EV (current) | $54M | XXX | $54M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 60.9x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (150.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.0x | XXX | XXX | XXX |
| P/E | — | XXX | (46.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BGM Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BGM Group Margins & Growth Rates
BGM Group's revenue in the last fiscal year declined by (39%).
BGM Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
BGM Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (39%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (220%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 11% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BGM Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BGM Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Türk İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| TScan Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Oncocross | XXX | XXX | XXX | XXX | XXX | XXX |
| Annovis Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Acrivon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BGM Group M&A Activity
BGM Group acquired XXX companies to date.
Last acquisition by BGM Group was on XXXXXXXX, XXXXX. BGM Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BGM Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBGM Group Investment Activity
BGM Group invested in XXX companies to date.
BGM Group made its latest investment on XXXXXXXX, XXXXX. BGM Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BGM Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BGM Group
| When was BGM Group founded? | BGM Group was founded in 2019. |
| Where is BGM Group headquartered? | BGM Group is headquartered in China. |
| How many employees does BGM Group have? | As of today, BGM Group has over 323 employees. |
| Who is the CEO of BGM Group? | BGM Group's CEO is Chen Xin. |
| Is BGM Group publicly listed? | Yes, BGM Group is a public company listed on Nasdaq. |
| What is the stock symbol of BGM Group? | BGM Group trades under BGM ticker. |
| When did BGM Group go public? | BGM Group went public in 2021. |
| Who are competitors of BGM Group? | BGM Group main competitors are Türk İlaç, TScan Therapeutics, Oncocross, Annovis Bio. |
| What is the current market cap of BGM Group? | BGM Group's current market cap is $66M. |
| What is the current revenue of BGM Group? | BGM Group's last fiscal year revenue is $25M. |
| What is the current EV/Revenue multiple of BGM Group? | Current revenue multiple of BGM Group is 2.1x. |
| Is BGM Group profitable? | No, BGM Group is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.